Pancreatic Differentiation of Patient-specific iPS Cells
Dr. Ikeda's lab has recently demonstrated successful differentiation of induced pluripotent stem (iPS) cells into glucose-responsive, insulin-producing cells in vitro.1 For a novel autologous iPS-mediated cell therapy for diabetes, there is a need to generate iPS cells from people with diabetes and differentiate derived cells into insulin-producing islet-like cells.
However, the feasibility of iPS generation from people with diabetes — or the pancreatic differentiation capability of derived iPS cells — remains elusive. The lab has recruited people with and without diabetes for iPS derivation and is currently analyzing their differentiation propensities and therapeutic effects in diabetic mouse models.
- Thatava T, et al. Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny. Gene Therapy. 2011;18:283.